AUTHORS
John Byrd, MD, Sergei Voloshin, MD2, Brian Ledwith, PhD3, Fraser Pickersgill, PhD4, Kate Dokukina, MD, PhD5, Ruben Karapetian, PhD6, Chia Sharpe, PhD7, Erin Hertlein, PhD8, Megan E. Johnstone, PhD9, Alexei Pushechnikov, PhD10, Evgenii Mikhailov, MD11, Konstantin Novoselov, MD12, Abdurahmon Kaumov, MD13, Nikolay Savchuk, PhD14, Iain Dukes, DPhil15, Amy Burd, PhD16
AFFILIATIONS
1 University Of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
2 Leningrad Regional Clinical Hospital, Leningrad, Russian Federation
3 Lomond Therapeutics, Dover, Delaware, United States
4 Lomond Therapeutics, Dover, Delaware, United States
5 Lomond Therapeutics, Dover, Delaware, United States
6 ChemDiv Inc, San Diego, California, United States
7 University of Cincinnati, Cincinnati, Ohio, United States
8 University of Cincinnati, Cincinnati, Ohio, United States
9 University of Cincinnati, Cincinnati, Ohio, United States
10 ChemDiv Inc, San Diego, California, United States
11 State Budgetary Institution of Healthcare Moscow Multidisciplinary Clinical Center, Moscow, Russian Federation
12 Novgorod Regional Clinical Hospital, Veliky Novgorod, Russian Federation
13 Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan, Chilanzar, Uzbekistan
14 Lomond Therapeutics, Dover, Delaware, United States
15 Lomond Therapeutics, Dover, Delaware, United States
16 Lomond Therapeutics, Dover, Delaware, United States
ABSTRACT
Background: B-cell lymphoma 2 (Bcl-2) is a member of the anti-apoptotic Bcl-2 family. Sensitivity to pharmaceutical disruption of Bcl-2 BH3 domain interactions with pro-apoptotic proteins characterizes diseases overtly responsive to this treatment. Combination treatments of the first-generation inhibitor venetoclax together with azacitidine have greatly impacted outcomes in unfit acute myeloid leukemia (AML). However, hematologic toxicity with the approved continuous dosing of venetoclax combined with azacitidine is often difficult to manage and efforts to further add treatments to this regimen have similarly been limited by prolonged hematologic toxicity. To mitigate the hematologic effects, immune suppression and drug-drug interactions (CYP3A4) observed with venetoclax, we developed lonitoclax using a rational design approach to create a structurally unique chemotype that binds outside of the P4 pocket of Bcl-2 to avoid inhibition of Bcl-xL as well as to have reduced interaction with CYP3A4 inhibitors. Pre-clinical studies in a syngeneic model demonstrated that lonitoclax and azacitidine had minimal immunosuppressive activity on B cells, CD8 T cells, and NK cells and was more effective than the combination of venetoclax and azacitidine.1 The safety of lonitoclax was further confirmed in a healthy volunteer study showing excellent tolerability and no CYP3A4 interaction with itraconazole.2 Herein, we report early results from our phase 1 combination of lonitoclax and azacitidine in relapsed AML.
Methods ZE50-0134-004 (NCT07303660) is an ongoing, Phase 1, multicenter, dose escalation and expansion study evaluating lonitoclax combined with azacitidine in R/R AML. The objective of this trial is to identify the recommended Phase 2 dose while exploring safety, early clinical activity and pharmacodynamic effects such as immune cell changes and efficacy via a plasma apoptosis assay [PAA]. The trial enrolled subjects ≥ 18 years with R/R AML including prior venetoclax/azacitidine, WBC < 25 × 109/L at time of treatment, ECOG 0-2, ≥ 60 mL/min/1.73m2 and adequate liver function. A 3+3 design with allowed backfill was utilized to enable the evaluation of six dose levels (100, 200, 350, 500, 650, and 800 mg dose twice daily (BID). No ramp-up dosing was utilized. A traditional published AML dose limiting toxicity (DLT) definition was utilized.
Results. As of July 30, 2026, a total of 14 R/R AML patients were enrolled across dose-escalation cohorts. Demographics of patients included median age 64 years (range 19-81), median prior regimens 2 (1 -5), median screening WBC 2.62 x 109/L (0.7-20.2 x 109/L). Four cohorts have completed enrollment with lonitoclax: 100, 200, 350, and 500 mg BID for 28 days combined with azacitidine (75 mg/m2 x 7 days). No DLT has been observed to this point. The ORR (CR, CRh, CRi MLFS) was 41.7% among evaluable patients (n=12), with a CR/CRh of 33.33%. In venetoclax-naïve patients (n = 6), the ORR was 50% with CR/CRh of 50%. Reduction of blood blast counts from baseline were observed across all dose levels. Pharmacokinetics across all doses demonstrated dose proportional increases in exposure. Pharmacodyanmic ex vivo procaspase activation was observed at the two highest dose levels.
Conclusion. In this ongoing dose escalation Phase 1 trial, lonitoclax combined with azacitidine was well tolerated with no DLTs observed and enrollment continues. This combination demonstrated promising antileukemic activity in heavily pretreated R/R AML patients including complete responses that appear to be dose dependent. Additional data will be updated at the time of the meeting
References:
Sharpe, C ASH 2023
Byrd, JC, EHA 2026
DISCLOSURES
John Byrd, MD: Eilean Therapeutics - Current holder of stock options in a privately-held company; UC Health - Ended employment in the past 24 months; Lomond Therapeutics - Current equity holder in private company; Eilean Therapeutics - Current equity holder in private company; Advocate Health - Honoraria; Eilean Therapeutics - Research Funding; Newave - Research Funding; OSU Drug Development Institute - Consultancy (Includes expert testimony); Lomond Therapeutics - Consultancy (Includes expert testimony); Orbimed - Consultancy (Includes expert testimony); Kartos - Consultancy (Includes expert testimony); Eilean Therapeutics - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); University of Cincinnatti - Current Employment; University of Pittsburgh - Current Employment; UPMC Hillman Cancer Center - Current Employment